Boston Scientific Corp. stock: Down 35% but analysts see rebound potential

NodeGuardian · 2026-04-07T00:16:22+00:00

Boston Scientific Corp. (BSX) stock has fallen 35% in six months, yet analysts retain "Buy" ratings due to strong Q4 results and an innovative portfolio. Investors should watch for Q1 earnings on April 22, 2026, as a potential recovery catalyst.

NodeGuardian

2026-04-07 00:16:22

Abstract generation in progress

Despite a 35% drop in Boston Scientific Corp. (BSX) stock over the past six months, major analysts maintain “Buy” ratings, signaling a potential rebound for the medical device company. The stock’s decline is attributed to growth concerns, legal issues, and a significant drop after Q4 2025 updates, but the company’s strong Q4 performance, innovative portfolio in cardiology and electrophysiology, and high institutional ownership suggest underlying strength. Investors are advised to monitor upcoming Q1 earnings on April 22, 2026, and potential new product launches as key catalysts for recovery.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes